$GMDA Announces Immune Reconstitution Data from Completed Phase 12 Clinical Study of NiCord Presented at 2019 TCT Annual Meeting httpswww.businesswire.comnewshome20190223005001enGamidaCellAnnouncesImmuneReconstitutionDataCompletedÂ
$GMDA Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting https://www.businesswire.com/news/home/20190223005001/en/Gamida-Cell-Announces-Immune-Reconstitution-Data-Completed …
More From BioPortfolio on "$GMDA Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting https://www.businesswire.com/news/home/20190223005001/en/Gamida-Cell-Announces-Immune-Reconstitution-Data-Completed …"